Our faculty author, co-author and contribute to more than 1500 peer-reviewed scientific publications each year. Find their recent publications below, and filter by division.
Search the faculty directory to find an individual's list of publications.
Publications
Reardon, David A., Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon, et al. “Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.” J Neurooncol 107, no. 1 (March 2012): 155–64. https://doi.org/10.1007/s11060-011-0722-2.
PMID
21986722
Wang, Tao, Catherine Huang, Alfonso Lopez-Coral, Kimberly A. Slentz-Kesler, Min Xiao, E John Wherry, and Russel E. Kaufman. “K12/SECTM1, an interferon-γ regulated molecule, synergizes with CD28 to costimulate human T cell proliferation.” J Leukoc Biol 91, no. 3 (March 2012): 449–59. https://doi.org/10.1189/jlb.1011498.
PMID
22184754
Wang, Li-E, Hongxia Ma, Katherine S. Hale, Ming Yin, Larissa A. Meyer, Hongliang Liu, Jie Li, et al. “Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.” J Cancer Res Clin Oncol 138, no. 3 (March 2012): 377–85. https://doi.org/10.1007/s00432-011-1103-0.
PMID
22146979
Tsivian, Matvey, Tiera Wright, Marva Price, Vladimir Mouraviev, John F. Madden, Masaki Kimura, Terrence Wong, and Thomas J. Polascik. “111-In-capromab pendetide imaging using hybrid-γ camera-computer tomography technology is not reliable in detecting seminal vesicle invasion in patients with prostate cancer.” Urol Oncol 30, no. 2 (March 2012): 150–54. https://doi.org/10.1016/j.urolonc.2009.12.005.
PMID
20189846
Reardon, David A., James E. Herndon, Katherine Peters, Annick Desjardins, April Coan, Emil Lou, Ashley Sumrall, et al. “Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.” J Neurooncol 107, no. 1 (March 2012): 213–21. https://doi.org/10.1007/s11060-011-0740-0.
PMID
21997879
Salz, Talya, Kevin C. Oeffinger, Mary S. McCabe, Tracy M. Layne, and Peter B. Bach. “Survivorship care plans in research and practice.” Ca Cancer J Clin 62, no. 2 (March 2012): 101–17. https://doi.org/10.3322/caac.20142.
PMID
22241452
Gaspar, Laurie E., Erica J. McNamara, E Greer Gay, Joe B. Putnam, Jeffrey Crawford, Roy S. Herbst, and James A. Bonner. “Small-cell lung cancer: prognostic factors and changing treatment over 15 years.” Clin Lung Cancer 13, no. 2 (March 2012): 115–22. https://doi.org/10.1016/j.cllc.2011.05.008.
PMID
22000695
Wampler, Meredith A., Mary Lou Galantino, Sujuan Huang, Laura S. Gilchrist, Victoria G. Marchese, G Stephen Morris, David A. Scalzitti, et al. “Physical activity among adult survivors of childhood lower-extremity sarcoma.” J Cancer Surviv 6, no. 1 (March 2012): 45–53. https://doi.org/10.1007/s11764-011-0187-5.
PMID
21681405
Fleming, Mark T., Guru Sonpavde, Michael Kolodziej, Sanjay Awasthi, Thomas E. Hutson, Danko Martincic, Ashutosh Rastogi, et al. “Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.” Clin Genitourin Cancer 10, no. 1 (March 2012): 6–14. https://doi.org/10.1016/j.clgc.2011.11.003.
PMID
22340631
Zurita, A. J., D. J. George, N. D. Shore, G. Liu, G. Wilding, T. E. Hutson, M. Kozloff, et al. “Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.” Ann Oncol 23, no. 3 (March 2012): 688–94. https://doi.org/10.1093/annonc/mdr349.
PMID
21821830